Proteomic analysis revealed significant downregulation of kinases UCK2 and GAK upon SIAIS117 treatment, but showed no effect on other kinases, such as EGFR mutations, IGF-1R, FLT3, ROS1, or Aurora A. Interestingly, SIAIS117 was also tested on several SCLC cell lines, which do not depend on ALK expression for proliferation, and showed notable cell-killing effects in these SCLC lines, indicating potential broader applicability. The gene discussed is ALK; the disease is small cell lung carcinoma.